Recombinant Escherichia coli heat-labile enterotoxin B subunit humoral adjuvant effect depends on dose and administration route

Information on the use of Escherichia coli heat-labile enterotoxin B subunit (LTB) as a parenteral adjuvant is scarce. We evaluate the adjuvant effect of different concentrations of recombinant LTB (rLTB), as well as the influence of administration route (intramuscular and subcutaneous) on mice immu...

Full description

Saved in:
Bibliographic Details
Published in:World journal of microbiology & biotechnology 2010-03, Vol.26 (3), p.489-495
Main Authors: Fischer, Geferson, Conceição, Fabricio R, Leite, Fábio P. L, Moraes, Carina M, Ferreira, Lílian N, Vilela, Camila O, Caetano, Clarissa F, Vargas, Gilberto D, Hübner, Sílvia O, Vidor, Telmo, Roehe, Paulo M
Format: Article
Language:English
Subjects:
Adjuvants
Applied Microbiology
Biochemistry
Biological and medical sciences
Biomedical and Life Sciences
Biotechnology
Chromatography
E coli
Environmental Engineering/Biotechnology
Fundamental and applied biological sciences. Psychology
Herpes viruses
Immune response
Immune system
Immunization
Immunohistochemistry
Life Sciences
Medical research
Microbiology
Original Paper
Proteins
Studies
Vaccines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Information on the use of Escherichia coli heat-labile enterotoxin B subunit (LTB) as a parenteral adjuvant is scarce. We evaluate the adjuvant effect of different concentrations of recombinant LTB (rLTB), as well as the influence of administration route (intramuscular and subcutaneous) on mice immune response. The use of 10 μg/dose of rLTB as adjuvant of an inactivated vaccine composed by Suid herpesvirus type 1 (SuHV-1), used to immunize mice intramuscularly, induced the highest average titers of anti-SuHV-1 antibodies (P < 0.05). The same vaccines used subcutaneously induced lower titers of antibodies. The lower the anti-rLTB humoral response determined by ELISA, the higher was its adjuvant activity. In the challenge experiment with SuHV-1, 56% (14/25) (P < 0.05) of the animals inoculated intramuscularly and 32% (8/25) inoculated subcutaneously survived, highlighting the influence of the concentration and the route of administration of rLTB on its performance as an adjuvant. Therefore, rLTB can significantly help in the induction of immunity against SuHV-1 in mice, especially if used intramuscularly in the concentration of 10 μg/dose, representing the best cost-benefit ratio.
ISSN:0959-3993
1573-0972
DOI:10.1007/s11274-009-0195-z